HOME > ACADEMIA
ACADEMIA
- COVID-19 Vaccines for Ages 5 to 11 Meaningful: Japan Pediatric Society
January 20, 2022
- Oita University Completes Dosing of Replicon RNA Vaccine in PI, Eyes Global PII/III
January 19, 2022
- Booster Effective against Omicron as Antibodies Rise: Kobe University
January 19, 2022
- Kyoto Univ., Takeda Succeed in Treating Muscular Dystrophy in Model Mice Using Genome Editing
December 10, 2021
- With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
- Swift Actions to Improve Diagnostic System, Control Costs Required to Prep for Potential Aducanumab Debut: JSDR Confab
November 30, 2021
- Anti-CGRP Antibodies Cut Headaches in 70% of Patients, but Cost Will Be Major Obstacle: Specialist
October 21, 2021
- Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
- For Hypertension, Entresto Expected as or More Effective than ARBs/ACE Inhibitors: Professor
October 21, 2021
- NCC Kicks Off Asia’s Clinical Data Sharing Project, Starting with Bowel Cancer
October 4, 2021
- NCC to Launch Search Portal for Cancer Genomic Data on Oct. 4; Support Drug Makers’ R&D
October 1, 2021
- Forxiga Could Treat 3 Million CKD Patients in Japan, Potentially Be 1st Choice Drug: Professor
October 1, 2021
- Evrysdi Offers New Option for SMA Patients with Scoliosis: KOL
September 29, 2021
- Use Oral Dexamethasone for COVID-19 Patients Requiring Oxygen: Scientific Societies
September 10, 2021
- Oita University to Begin PI Study for Replicon RNA Vaccine in October
September 10, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Darzquro Expected to Treat 900 AL Amyloidosis Patients in Japan Annually: Specialist
September 6, 2021
- 1st COVID-19 Delta Variant Mutation Found in Japan: TMDU
August 31, 2021
- TMDU, Takeda Running Joint Research on Heteroduplex Oligonucleotide for Neuro Diseases
August 24, 2021
- Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
August 16, 2021
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…